CD86 and myeloid sarcoma: We immunolabeled both lesions with antibodies against the cellular and activation markers CD68, S100B, CD3, PLP, CD45, CD86, ferritin, HLA-DR, LAMP1, Mac2, MerTK, TIM-3 and vimentin; all known to be expressed in MS lesions [2, 6, 13, 15, 31, 42, 44, 45].